Zelluna appoints Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026, succeeding Hans Vassgård Eid. Geir Christian brings extensive experience in the Norwegian biotech industry, having held senior leadership roles in companies like Algeta and Photocure. He has been with Zelluna for over seven years, contributing to finance and operations. Geir Christian is excited to lead Zelluna through its first-in-human study with the TCR-NK platform. Zelluna is a biotech company developing allogeneic TCR-NK cell therapies for cancer treatment, with the lead program targeting the MAGE-A4 tumor antigen expected to enter clinical trials in 2026.

Read more at GlobeNewswire: Zelluna ASA Announces Appointment of Geir Christian Melen